文献速递颈动脉与弓上血管

围术期P2Y12抑制剂通过主要减少卒中改善颈动脉支架置入术后围术期结局

Periprocedural P2Y12 inhibitors improve perioperative outcomes after carotid stenting by primarily decreasing strokes.
PubMed 文献 · J Vasc Surg · 2022-10-31

基于血管质量倡议(VQI)2007至2020年31036例颈动脉支架置入(CAS)手术的回顾性分析显示,围术期使用P2Y12抑制剂与围术期神经事件(2.3% vs 3.9%,P < .001)和死亡率(0.6% vs 2.1%,P < .001)显著降低相关,对心肌梗死无影响。多变量分析显示P2Y12抑制剂独立显著降低围术期卒中(OR 0.29,95%CI 0.25-0.33),且不同P2Y12抑制剂似乎等效。

要点

  • 围术期P2Y12抑制剂与围术期神经事件降低相关(2.3% vs 3.9%,P < .001)。
  • P2Y12抑制剂独立显著降低围术期卒中(OR 0.29,95%CI 0.25-0.33)。
  • 不同P2Y12抑制剂在降低围术期神经事件率上似乎等效。

核心结论

  • 围术期P2Y12抑制剂似乎显著降低经颈动脉血运重建(TCAR)和经股动脉颈动脉支架置入(TF-CAS)在有症状和无症状患者中的围术期神经事件率,应强烈考虑使用。
  • 有P2Y12抑制剂禁忌证的患者可能不适合任何CAS手术。
  • 其他类型P2Y12抑制剂似乎与氯吡格雷等效。
  • VQI分析显示即使TCAR病例,围术期仅87.3%患者似乎使用P2Y12抑制剂,存在显著改善空间。

研究设计与样本

  • 使用血管质量倡议(VQI)2007至2020年数据,纳入所有TCAR和TF-CAS手术,共31036例CAS手术(TCAR 49.8%,TF-CAS 50.2%)。
  • 根据围术期P2Y12抑制剂使用及症状状态对患者进行分层。

主要发现

  • 全队列围术期神经事件率为2.6%。
  • 使用P2Y12抑制剂者围术期神经事件率显著低于未使用者(2.3% vs 3.9%;P < .001)。
  • 使用P2Y12抑制剂者死亡率显著低于未使用者(0.6% vs 2.1%;P < .001)。
  • 心肌梗死率无影响。
  • 多变量分析显示P2Y12抑制剂独立显著降低围术期卒中(OR 0.29;95%CI 0.25-0.33)。

临床怎么用

  • 作者认为围术期P2Y12抑制剂似乎显著降低TCAR和TF-CAS围术期神经事件率,应强烈考虑使用。
  • 作者认为有P2Y12抑制剂禁忌证的患者可能不适合任何CAS手术。
  • 作者认为其他类型P2Y12抑制剂似乎与氯吡格雷等效。
  • 作者指出VQI分析显示即使TCAR病例,围术期仅87.3%患者似乎使用P2Y12抑制剂,存在显著改善空间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The continuation of antiplatelet agents in the periprocedural period around carotid stenting (CAS) procedures is felt to be mandatory to minimize the risk of periprocedural stroke. However, the optimal antiplatelet regimen is unclear, with some advocating dual antiplatelet therapy, and others supporting the use of P2Y12 inhibitors alone. The objective of this study was to evaluate the periprocedural effect of P2Y12 inhibitors for CAS. METHODS: The Vascular Quality Initiative was used from years 2007 to 2020. All transcarotid artery revascularization (TCAR) and transfemoral carotid artery stenting (TF-CAS) procedures were included. Patients were stratified based on perioperative use of P2Y12 inhibitors as well as symptomatic status. Primary end points were perioperative neurological events (strokes and transient ischemic attacks). Secondary end points were mortality and myocardial infarction. RESULTS: A total of 31,036 CAS procedures were included for analysis, with 49.8% TCAR and 50.2% TF-CAS cases; 63.8% of patients were male and 82.3% of patients were on a P2Y12 inhibitor. P2Y12 inhibitor use was more common in males, asymptomatic patients, those older than 70 years, and concurrent statin use. P2Y12 inhibitors were more likely to be used in TCAR cases than in TF-CAS cases (87.3% vs 76.8%; P < .001). The rate of periprocedural neurological events in the whole cohort was 2.6%. Patients on P2Y12 inhibitors were significantly less likely to experience a periprocedural neurological event (2.3% vs 3.9%; P < .001) and mortality (0.6% vs 2.1%; P < .001) than those who were not on a P2Y12 inhibitor. There was no effect on the rates of myocardial infarction. On multivariate analysis, both symptomatic and asymptomatic patients on P2Y12 inhibitors were significantly less likely to develop perioperative neurological events. Additionally, the use of P2Y12 inhibitors demonstrated an independent significant effect in reducing of the rate of perioperative stroke (odds ratio, 0.29; 95% confidence interval, 0.25-0.33). Finally, additional analysis of the types of P2Y12 inhibitors used revealed that all seemed to be equally effective in decreasing the periprocedural neurological event rate. CONCLUSIONS: The use of perioperative P2Y12 inhibitors seems to markedly decrease the perioperative neurological event rate with TCAR and TF-CAS in both symptomatic and asymptomatic patients and should be strongly considered. Patients with contraindications to P2Y12 inhibitors may not be appropriate candidates for any CAS procedure. Additionally, alternative types of P2Y12 inhibitors seem to be equally effective as clopidogrel. Finally, an analysis of the Vascular Quality Initiative demonstrates that, even for TCAR cases, only 87.3% of patients seem to be on P2Y12 inhibitors in the periprocedural period, leaving room for significant improvement.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Heib A, Chang H, Rockman C, et al. Periprocedural P2Y12 inhibitors improve perioperative outcomes after carotid stenting by primarily decreasing strokes. J Vasc Surg. 2022. PMID: 36328140. doi:10.1016/j.jvs.2022.10.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。